It demonstrates that smart insulin pen systems support MDI therapy patients in daily dosing decisions and may facilitate communication with the diabetes care team, which provides precision insulin management for all individuals on insulin therapy regardless of delivery method. This evidence concerns the gene INS and diabetes mellitus.